Candriam S.C.A. Sells 3,654 Shares of McKesson Corporation $MCK

Candriam S.C.A. cut its stake in shares of McKesson Corporation (NYSE:MCK) by 1.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 206,756 shares of the company’s stock after selling 3,654 shares during the period. McKesson comprises approximately 0.8% of Candriam S.C.A.’s holdings, making the stock its 23rd largest position. Candriam S.C.A. owned approximately 0.18% of McKesson worth $177,175,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Secure Asset Management LLC increased its holdings in McKesson by 484.8% during the second quarter. Secure Asset Management LLC now owns 2,123 shares of the company’s stock valued at $1,604,000 after buying an additional 1,760 shares during the last quarter. BayBridge Capital Group LLC raised its position in McKesson by 268.0% in the second quarter. BayBridge Capital Group LLC now owns 1,943 shares of the company’s stock worth $1,468,000 after acquiring an additional 1,415 shares during the period. Royal London Asset Management Ltd. raised its position in McKesson by 1.1% in the second quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company’s stock worth $84,809,000 after acquiring an additional 1,216 shares during the period. Benchmark Investment Advisors LLC purchased a new position in shares of McKesson during the 2nd quarter worth $441,000. Finally, Summit Global Investments purchased a new position in shares of McKesson during the 2nd quarter worth $1,159,000. 85.07% of the stock is owned by institutional investors.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Insider Transactions at McKesson

In other news, Director Bradley Lerman sold 301 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO B Jr sold 111 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the sale, the chief accounting officer owned 521 shares in the company, valued at $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,462 shares of company stock valued at $2,511,106 over the last three months. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MCK. Evercore reissued an “outperform” rating and set a $950.00 price objective (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Wall Street Zen raised McKesson from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Weiss Ratings raised McKesson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, September 4th. Robert W. Baird set a $1,015.00 target price on McKesson in a research report on Thursday, August 6th. Finally, Citigroup lifted their target price on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,026.18.

McKesson Trading Down 1.0%

Shares of NYSE:MCK opened at $1,060.79 on Friday. The stock has a 50 day moving average of $938.13 and a 200 day moving average of $868.12. The company has a market cap of $122.48 billion, a PE ratio of 27.28, a price-to-earnings-growth ratio of 2.08 and a beta of 0.27. McKesson Corporation has a 12-month low of $723.68 and a 12-month high of $1,121.50.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, topping analysts’ consensus estimates of $10.72 by $0.96. McKesson had a net margin of 1.12% and a negative return on equity of 202.94%. The company had revenue of $110.96 billion for the quarter, compared to analysts’ expectations of $109.90 billion. During the same quarter last year, the business earned $9.86 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year. Equities research analysts predict that McKesson Corporation will post 46.21 earnings per share for the current fiscal year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio is 9.67%.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.